Steven Seedhouse
Stock Analyst at Raymond James
(3.22)
# 970
Out of 4,847 analysts
171
Total ratings
41.57%
Success rate
2.44%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $73 → $77 | $45.97 | +67.50% | 19 | May 13, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $10.80 | +585.19% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.25 | +60.00% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $16.69 | +67.77% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $4.76 | +888.43% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.81 | +1,134.57% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $10.73 | +86.39% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $26.12 | +298.16% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.82 | +1,108.79% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $17.55 | +219.09% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $10.11 | +384.67% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $1.78 | +686.52% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $108.91 | -14.61% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $31.74 | +114.24% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $19.14 | +453.81% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $3.85 | +289.61% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $12.70 | +340.94% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.36 | +4,781.45% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $7.16 | +696.09% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.01 | +2,078.22% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.77 | +860.45% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $2.77 | +1,163.54% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $43.13 | -11.89% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $33.17 | +114.05% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.16 | +332.90% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $21.86 | +73.83% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $12.81 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.45 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $131.14 | - | 2 | Apr 23, 2020 | |
Mirum Pharmaceuticals
May 13, 2025
Maintains: Strong Buy
Price Target: $73 → $77
Current: $45.97
Upside: +67.50%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $10.80
Upside: +585.19%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.25
Upside: +60.00%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $16.69
Upside: +67.77%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $4.76
Upside: +888.43%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.81
Upside: +1,134.57%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $10.73
Upside: +86.39%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $26.12
Upside: +298.16%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.82
Upside: +1,108.79%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $17.55
Upside: +219.09%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $10.11
Upside: +384.67%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.78
Upside: +686.52%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $108.91
Upside: -14.61%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $31.74
Upside: +114.24%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $19.14
Upside: +453.81%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $3.85
Upside: +289.61%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $12.70
Upside: +340.94%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.36
Upside: +4,781.45%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $7.16
Upside: +696.09%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.01
Upside: +2,078.22%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.77
Upside: +860.45%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $2.77
Upside: +1,163.54%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $43.13
Upside: -11.89%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $33.17
Upside: +114.05%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.16
Upside: +332.90%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $21.86
Upside: +73.83%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $12.81
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.45
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $131.14
Upside: -